Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

721
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
721
Cancer Vaccines01:30

Cancer Vaccines

548
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
548
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uterine serous carcinoma and germline genetic testing: patterns of referral, completion and pathogenic variant detection.

Journal of medical genetics·2026
Same author

Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes.

Cancers·2025
Same author

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Durable response to an anti-CD25 antibody-drug conjugate and anti-PD-1 antibody in ovarian carcinoma: a case report.

Immunotherapy·2025
Same author

Active Forms of Chemerin Are Elevated in Human and Mouse Ovarian Carcinoma.

Biomedicines·2025
Same author

Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer.

Gynecologic oncology reports·2025

Related Experiment Video

Updated: Oct 8, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.1K

Cell-based immunotherapies in gynecologic cancers.

Susan M Lang1, Oliver Dorigo

  • 1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford School of Medicine, Stanford Cancer Institute, Stanford, California, USA.

Current Opinion in Obstetrics & Gynecology
|December 30, 2021
PubMed
Summary

Recent advancements in cell-based immunotherapy, including chimeric antigen receptor (CAR) technology and cell-based vaccines, show promising clinical efficacy for gynecologic cancers.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.6K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

Related Experiment Videos

Last Updated: Oct 8, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.1K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.6K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Gynecologic cancers represent a significant global health challenge.
  • Existing treatments have limitations, driving the need for novel therapeutic strategies.

Purpose of the Study:

  • To review recent developments in cell-based immunotherapy for gynecologic cancers.
  • To highlight advancements in chimeric antigen receptor (CAR) technology and cell-based vaccines.

Main Methods:

  • Review of current literature on cell-based immunotherapies.
  • Analysis of recent clinical trial data for gynecologic cancer treatments.

Main Results:

  • Chimeric antigen receptor (CAR) technology is expanding beyond T-cells to include natural killer cells and macrophages.
  • Cell-based vaccines are demonstrating promising results in clinical trials.
  • Cell-based immunotherapies show potential for clinical efficacy in select gynecologic cancer patients.

Conclusions:

  • Cell-based immunotherapies are a rapidly evolving field in gynecologic oncology.
  • These novel approaches offer hope for improved patient outcomes.